Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.

about

Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.

Item

http://www.wikidata.org/entity/Q55035317

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Survival prediction based on q ...... ioma treated with bevacizumab.

@en

Survival prediction based on q ...... ioma treated with bevacizumab.

@nl

type

Item

label

Survival prediction based on q ...... ioma treated with bevacizumab.

@en

Survival prediction based on q ...... ioma treated with bevacizumab.

@nl

prefLabel

Survival prediction based on q ...... ioma treated with bevacizumab.

@en

Survival prediction based on q ...... ioma treated with bevacizumab.

@nl

P1476

Survival prediction based on q ...... ioma treated with bevacizumab.

@en

P2093

Alok A Bhatt

http://www.w3.org/2001/XMLSchema#string

Manisha Mangla

http://www.w3.org/2001/XMLSchema#string

Mary Tenenbaum

http://www.w3.org/2001/XMLSchema#string

Pradeep Goyal

http://www.w3.org/2001/XMLSchema#string

Puneet S Kochar

http://www.w3.org/2001/XMLSchema#string

Rajiv Mangla

http://www.w3.org/2001/XMLSchema#string

Sonali Gupta

http://www.w3.org/2001/XMLSchema#string

Yogesh Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

P304

268-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/QIMS.2018.04.05

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774180

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5941208

http://www.w3.org/2001/XMLSchema#string